重组人脑利钠肽对失代偿性心力衰竭疗效的观察
|
摘要
心力衰竭(CHF)是指由于各种原因导致心脏功能受损,特别是心室肌收缩和或舒张功能受损,心脏不能维持足够的心输出量以满足身体对代谢的需要和静脉血流受阻的状态,是各种心脏疾病发展的终末阶段并导致心功能不全而表现的一组临床综合征,主要表现是呼吸困难和疲乏,在人群中高发病率和死亡率。CHF的病理生理学表现主要在于心室重构和神经-内分泌-细胞因子系统的激活。这些被激活的神经-内分泌-细胞因子系统主要包括:肾上腺素能系统、肾素-血管紧张素-醛固酮系统(RASS)、细胞因子系统以及肽类信号系统中的具收缩血管作用的内皮素系统和扩张血管功能的钠利尿肽系统,是CHF发生后的一系列维持循环功能的代偿活动,但同样也导致了心室重构和CHF症状加重,使病情恶化。脑利钠肽(brain natriuretic peptide,BNP)和心房利钠肽(atrialnatriuretic peptide,ANP)是钠利尿肽系统的主要成员。BNP是由心室分泌,半衰期为18 min,随CHF的加重而分泌增加,代偿性拮抗肾上腺素能、肾素-血管紧张素-醛固酮和内皮素系统的活性,松弛血管平滑肌细胞而扩张外周动静脉血管,增加钠的排泄而利钠利尿,减轻心脏的前后负荷,有益于CHF病情的缓解。
重组人脑利钠肽(recombinant human brain natriuretiC peptide,rhBNP)是利用DNA重组技术产生的高纯度冻干粉针剂,与内源性BNP具有相同的32个氨基酸序列和空间立体结构,因此具有相同的生物活性和作用机制,它通过与利钠肽受体结合,激活结合型鸟苷酸环化酶,升高细胞内环一磷酸鸟苷(cyclicguanosine monophosphate,cGMP)浓度,是一类具有血管扩张特性的新药物,它没有强心作用,不抑制磷酸二酯酶,不依赖β肾上腺素能受体,通过增加cGMP发挥作用,具有排钠利尿,降低肺毛细血管压、全身血管阻力和肺动脉压,增加心脏指数和射血分数,减少血浆醛固酮水平。另外,在严重心力衰竭阶段存在内源性BNP相对不足或BNP抵抗。因此,补充外源性BNP可用于失代偿性心力衰竭(decompensated heart failure,DHF)的治疗。rhBNP首先在美国研制成功并已成为新一代静脉注射用治疗失代偿性CHF的药物。
目的比较重组人脑利钠肽(rhBNP)和硝酸甘油对失代偿性心力衰竭的临床疗效。
方法我院50例失代偿性心力衰竭住院患者随机分为硝酸甘油组和rhBNP组,分别记录两组患者给药前及给药后30min、6h及24h的呼吸困难程度以及整体临床情况,以及用药24h后液体的出入量和血流动力学参数和72h后室性心律失常情况。其中硝酸甘油组使用硝酸甘油开始剂量为5μg/min,每3～5分钟增加5μg/min,根据个体的血流动力学参数来调整用量;rhBNP组使用rhBNP,首先以1.5μg/kg弹丸式静脉冲击,随后以0.0075μg·kg~(-1)·min~(-1)连续静脉滴注72h。应用SPSS15.0软件进行统计分析,显著性水平设为0.05(双侧)。计量资料比较采用独立样本t检验,计数资料比较采用Pearson卡方检验,等级资料采用Wilcoxon W检验或Kruskal Wallis检验等统计方法。
结果rhBNP组患者静脉给药后30min和6h的呼吸困难好转程度(P值分别为0.042和0.019)和整体临床状况好转程度(P值分别是0.018和0.044)均显著优于硝酸甘油组,24h后两组未有明显差异(P值分别是0.192和0.179);用药24h后的尿量rhBNP组(1513.8±242.9)ml显著多于硝酸甘油组(1341.2±239.7)ml(P=0.015):用药24h时rhBNP组患者射血分数的增加以及肺动脉压和收缩压的降低均显著多于硝酸甘油组(P值分别是0.001、0.000及0.002),用药72h后rhBNP组室性期前收缩、成对期前收缩和阵发性室性心动过速等室性心律失常发作的次数显著减少(P值分别是0.000、0.001和0.002)。
结论rhBNP通过促进尿量的排泄、降低肺动脉压及增加左室射血分数等途径明显改善失代偿性心力衰竭患者呼吸困难和整体临床状况,以及显著减少室性心律失常的发作。
Congestive heart failure (CHF) refers to a variety of causes impaired heart function, particularly ventricular systolic and diastolic function damaged, heart can not maintain an adequate cardiac output to meet the needs of the body metabolism and venous blood flow obstruction state, CHF is a group of clinical syndrome of the end stage of heart disease, and the main complaints are dyspnea and fatigue, and CHF is high morbidity and mortality. The main pathophysiology of CHF is the ventricular remodeling and nerve-endocrine-cytokine activation system. Activation of these neurons - endocrine - cytokines system include: adrenergic system, renin-angiotensin-aldosterone system(RASS), cytokines and signal peptide systems which include endothelin system and natriuretic peptide system, endothelin is a shrinking role of the vascular system and natriuretic peptide is expansion of the vascular function, neurons - endocrine - cytokines system are a series of compensatory activities of circulatory function after CHF, but these also led to the left ventricular remodeling and CHF symptoms increase, and the condition worsened. Brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) are the principal members of natriuretic peptide system. BNP is secreted by ventricular, half-life is 18 min, with the CHF increased secretion increased, and it compensatory antagonism the activity of adrenergic antagonist, renin - angiotensin - aldosterone and endothelin system, and it relaxates the vascular smooth muscle cells and expansese the peripheral arteriovenous, and increasese sodium excretion and natriuretic, these reduce the preload and afterload of heart, so BNP can release CHF conditions.
RhBNP that using recombinant DNA technologies to produce is high-purity freeze-dried powder, and it with the same 32 amino acid sequence and three-dimensional structure of the endogenous BNP ,and therefore they have the same biological activity and mechanisms. BNP binding natriuretic peptide receptor to activate the combination guanylate cyclase, and increasing guanosine monophosphate (cGMP) concentration inner the cell,it is a class new drug of blood vessel dilation , it does not have strong hearts, not inhibit phosphodiesterase, do not rely onβ-adrenergic receptors, BNP increasing cGMP plays roles of natriuretic and reducing pulmonary capillary pressure and systemic vascular resistance and pulmonary artery pressure,increasing cardiac index and ejection fraction, but also does not affect synthesis of renin-- angiotensin-aldosterone system of reducing plasma aldosterone levels. RhBNP first produced in the United States and has developed a new generation of intravenous treatment of decompensated CHF drugs. In more severe stages of heart failure, there may be a relative shortage of endogenous BNP or BNP resistance. Therefore, the exogenous BNP may be the treatment of decompensated heart failure (DHF).
Objective To compare the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) and nitroglycerin on acute decompensated heart failure (ADHF). Methods 50 cases of ADHF patients were randomly divided into rhBNP group and the nitroglycerin groups. In all patients, dyspnea and global clinical status were assessed at 30 minutes, 6 hours and 24 hours after the use of study drug, and the input liquid and urine and hemodynamic parameters were recorded after administration 24 hours. First the nitroglycerin group used the dose of nitroglycerin 5μg / min, and then every three to five minutes increased 5μg / min, according to the hemodynamic parameters of the individual to adjust the dosage; and the rhBNP group use rhBNP (first 1.5μg per kilogram of body weight bolus intravenous followed by a infusion of 0.0075μg per kilogram of body weight per minute for 72 hours). Application SPSS15.0 software for statistical analysis, as a significant level of 0.05 (bilateral). Comparison of measurement data using independent samples t-test, compared with the count data using Pearson Chi-square test, grading information using Wilcoxon W test or Kruskal Wallis test . Results The improved level of dyspnea and global clinical status of the rhBNP group were significantly better than those of the nitroglycerin group at 30 minutes and 6 hours after the start of study drug (the P value is 0.042 and 0.019 for dyspnea ,and it is 0.018 and 0.044 for global clinical status, respectively); after 24 hours those were no significant difference in the two groups (P values were 0.192 and 0.179); After 24 hours ,the urine of rhBNP group (1513.8±242.9) ml were significantly more than that of the nitroglycerin group (1341.2±239.7) ml (the P value is 0.015) , and the increase in ejection fraction and the decrease in pulmonary arterial pressure and systolic blood pressure of the rhBNP group were significantly more than those of the nitroglycerin group (P values were 0.001,0.000 and 0.002, respectively); After 72 hours the number of premature ventricular contraction and couplets premature beats and paroxysmal ventricular tachycardia of the rhBNP group were significantly lower than those of the nitroglycerin group (P values were 0, 0.001 and 0.002). Conclusion RhBNP promote the excretion of urine, decrease pulmonary artery pressure and increase left ventricular ejection fraction, so rhBNP can significantly improved dyspnea and global clinical status for the patients of decompensated heart failure, and significantly reduce the onset of ventricular arrhythmias.
重组人脑利钠肽(recombinant human brain natriuretiC peptide,rhBNP)是利用DNA重组技术产生的高纯度冻干粉针剂,与内源性BNP具有相同的32个氨基酸序列和空间立体结构,因此具有相同的生物活性和作用机制,它通过与利钠肽受体结合,激活结合型鸟苷酸环化酶,升高细胞内环一磷酸鸟苷(cyclicguanosine monophosphate,cGMP)浓度,是一类具有血管扩张特性的新药物,它没有强心作用,不抑制磷酸二酯酶,不依赖β肾上腺素能受体,通过增加cGMP发挥作用,具有排钠利尿,降低肺毛细血管压、全身血管阻力和肺动脉压,增加心脏指数和射血分数,减少血浆醛固酮水平。另外,在严重心力衰竭阶段存在内源性BNP相对不足或BNP抵抗。因此,补充外源性BNP可用于失代偿性心力衰竭(decompensated heart failure,DHF)的治疗。rhBNP首先在美国研制成功并已成为新一代静脉注射用治疗失代偿性CHF的药物。
目的比较重组人脑利钠肽(rhBNP)和硝酸甘油对失代偿性心力衰竭的临床疗效。
方法我院50例失代偿性心力衰竭住院患者随机分为硝酸甘油组和rhBNP组,分别记录两组患者给药前及给药后30min、6h及24h的呼吸困难程度以及整体临床情况,以及用药24h后液体的出入量和血流动力学参数和72h后室性心律失常情况。其中硝酸甘油组使用硝酸甘油开始剂量为5μg/min,每3～5分钟增加5μg/min,根据个体的血流动力学参数来调整用量;rhBNP组使用rhBNP,首先以1.5μg/kg弹丸式静脉冲击,随后以0.0075μg·kg~(-1)·min~(-1)连续静脉滴注72h。应用SPSS15.0软件进行统计分析,显著性水平设为0.05(双侧)。计量资料比较采用独立样本t检验,计数资料比较采用Pearson卡方检验,等级资料采用Wilcoxon W检验或Kruskal Wallis检验等统计方法。
结果rhBNP组患者静脉给药后30min和6h的呼吸困难好转程度(P值分别为0.042和0.019)和整体临床状况好转程度(P值分别是0.018和0.044)均显著优于硝酸甘油组,24h后两组未有明显差异(P值分别是0.192和0.179);用药24h后的尿量rhBNP组(1513.8±242.9)ml显著多于硝酸甘油组(1341.2±239.7)ml(P=0.015):用药24h时rhBNP组患者射血分数的增加以及肺动脉压和收缩压的降低均显著多于硝酸甘油组(P值分别是0.001、0.000及0.002),用药72h后rhBNP组室性期前收缩、成对期前收缩和阵发性室性心动过速等室性心律失常发作的次数显著减少(P值分别是0.000、0.001和0.002)。
结论rhBNP通过促进尿量的排泄、降低肺动脉压及增加左室射血分数等途径明显改善失代偿性心力衰竭患者呼吸困难和整体临床状况,以及显著减少室性心律失常的发作。
Congestive heart failure (CHF) refers to a variety of causes impaired heart function, particularly ventricular systolic and diastolic function damaged, heart can not maintain an adequate cardiac output to meet the needs of the body metabolism and venous blood flow obstruction state, CHF is a group of clinical syndrome of the end stage of heart disease, and the main complaints are dyspnea and fatigue, and CHF is high morbidity and mortality. The main pathophysiology of CHF is the ventricular remodeling and nerve-endocrine-cytokine activation system. Activation of these neurons - endocrine - cytokines system include: adrenergic system, renin-angiotensin-aldosterone system(RASS), cytokines and signal peptide systems which include endothelin system and natriuretic peptide system, endothelin is a shrinking role of the vascular system and natriuretic peptide is expansion of the vascular function, neurons - endocrine - cytokines system are a series of compensatory activities of circulatory function after CHF, but these also led to the left ventricular remodeling and CHF symptoms increase, and the condition worsened. Brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) are the principal members of natriuretic peptide system. BNP is secreted by ventricular, half-life is 18 min, with the CHF increased secretion increased, and it compensatory antagonism the activity of adrenergic antagonist, renin - angiotensin - aldosterone and endothelin system, and it relaxates the vascular smooth muscle cells and expansese the peripheral arteriovenous, and increasese sodium excretion and natriuretic, these reduce the preload and afterload of heart, so BNP can release CHF conditions.
RhBNP that using recombinant DNA technologies to produce is high-purity freeze-dried powder, and it with the same 32 amino acid sequence and three-dimensional structure of the endogenous BNP ,and therefore they have the same biological activity and mechanisms. BNP binding natriuretic peptide receptor to activate the combination guanylate cyclase, and increasing guanosine monophosphate (cGMP) concentration inner the cell,it is a class new drug of blood vessel dilation , it does not have strong hearts, not inhibit phosphodiesterase, do not rely onβ-adrenergic receptors, BNP increasing cGMP plays roles of natriuretic and reducing pulmonary capillary pressure and systemic vascular resistance and pulmonary artery pressure,increasing cardiac index and ejection fraction, but also does not affect synthesis of renin-- angiotensin-aldosterone system of reducing plasma aldosterone levels. RhBNP first produced in the United States and has developed a new generation of intravenous treatment of decompensated CHF drugs. In more severe stages of heart failure, there may be a relative shortage of endogenous BNP or BNP resistance. Therefore, the exogenous BNP may be the treatment of decompensated heart failure (DHF).
Objective To compare the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) and nitroglycerin on acute decompensated heart failure (ADHF). Methods 50 cases of ADHF patients were randomly divided into rhBNP group and the nitroglycerin groups. In all patients, dyspnea and global clinical status were assessed at 30 minutes, 6 hours and 24 hours after the use of study drug, and the input liquid and urine and hemodynamic parameters were recorded after administration 24 hours. First the nitroglycerin group used the dose of nitroglycerin 5μg / min, and then every three to five minutes increased 5μg / min, according to the hemodynamic parameters of the individual to adjust the dosage; and the rhBNP group use rhBNP (first 1.5μg per kilogram of body weight bolus intravenous followed by a infusion of 0.0075μg per kilogram of body weight per minute for 72 hours). Application SPSS15.0 software for statistical analysis, as a significant level of 0.05 (bilateral). Comparison of measurement data using independent samples t-test, compared with the count data using Pearson Chi-square test, grading information using Wilcoxon W test or Kruskal Wallis test . Results The improved level of dyspnea and global clinical status of the rhBNP group were significantly better than those of the nitroglycerin group at 30 minutes and 6 hours after the start of study drug (the P value is 0.042 and 0.019 for dyspnea ,and it is 0.018 and 0.044 for global clinical status, respectively); after 24 hours those were no significant difference in the two groups (P values were 0.192 and 0.179); After 24 hours ,the urine of rhBNP group (1513.8±242.9) ml were significantly more than that of the nitroglycerin group (1341.2±239.7) ml (the P value is 0.015) , and the increase in ejection fraction and the decrease in pulmonary arterial pressure and systolic blood pressure of the rhBNP group were significantly more than those of the nitroglycerin group (P values were 0.001,0.000 and 0.002, respectively); After 72 hours the number of premature ventricular contraction and couplets premature beats and paroxysmal ventricular tachycardia of the rhBNP group were significantly lower than those of the nitroglycerin group (P values were 0, 0.001 and 0.002). Conclusion RhBNP promote the excretion of urine, decrease pulmonary artery pressure and increase left ventricular ejection fraction, so rhBNP can significantly improved dyspnea and global clinical status for the patients of decompensated heart failure, and significantly reduce the onset of ventricular arrhythmias.
引文
[1]ACC/ AHA Guidelines for the evaluation and management of chronic heart failure.Circulation,2001,104:2996-3007.
[2]Massie BM,Shah NB.Evolving trends in the epidemiologic factors of heart failure:rational for preventive strategies and comprehensive disease management.Am Heart J,1997,133:703-712.
[3]2002 Heart and stroke statistica update.Dallas:American Heart Association,2001
[4]John R.Kapoor,Mar A.Perazella.Diagnostic and Therapeutic Approach to Acute Decompensated Heart Failure.The American Journal of Medicine.(2007) 120,121-127.
[5]HoKKL,Pinsky JL,Kannel WB,et al.The epidemiology of heart failure:the Framingham study.J Am Coll Cardiol,1993,22(SupplA):6A-13A
[6]Guidelines for the diagnosis and treatment of chronic heart failure:task force for the diagnosis and treatment of chronic heart failure.Eur Heart J,2001,22:1527-1560.
[7]顾东风,黄广勇,吴锡桂等.中国心力衰竭流行病学调查及其患病率.中华心血管病杂志,2003,(1).
[8]Lan'y A.Allen,Christopher M.O'Connor.Management of acute decompensated heart failure.CMAJ,2007;176(6),797-805
[9]Brunner-La,Rocca,H.P.,D.M.Kaye,et al.Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects.J Am Coll Cardiol 2001,37(5):1221-7.
[10]MaiselA.B --type natriuretic peptid elevels:A potential novel white count,for congestive heart failure. J Card Fail 2001; 7:183 — 193
[11]De Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile eurohormone. Chest; 2004; 125(2): 652-68
[12] Chen HH,Burnett JC.Natriuretic peptides in the pathophysiology of congestive heart failure.Curr Cardiol Rep,2000;2; 198-205
[13] Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007; 50(19):1835-40
[14] ADHERE:the third quarter 2003 national benchmark report.
[15] Nieminen MS, Bohm M, Cowie MR, et al .Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J.2005; 26(4):384-416
[16] Publication Committee for the VMAC Investigators.Intravenous nesiritide and nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial [J]. JAMA, 87(12):1531-1540.
[17] Sacchetti A, Ramoska E, Moakes ME, et al. Effect of ED management on ICU use in acute pulmonary edema. Am J Emerg Med. 1999; 17:571-574.
[18] Edoute Y, Roguin A, Behar D, et al. Prospective evaluation of pulmonary edema. Crit Care Med.2000; 28:330-335.
[19] Peacock F, Emerman C, Costanzo M, et al. Early initiation of intravenous Vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE registry database. Ann Emerg Med. 2003; 42:s29.
[20] John R. Kapoor, Mark A. Perazella, et al.Diagnostic and Therapeutic Approach to Acute Decompensated Heart Failure. The American Journal of Medicine, 2007; 120:121-127
[21] Sudoh T, Kangawa K,Minamino N, et al.A new natriuretic pep tide in porcine brain [J]. Nature, 1988, 332 (10): 78-86
[22] KUHN M.Molecular physiology of natriuretic peptide signaling[J]. Basic Res Cardiol, 2004, 99 (2): 76 - 82.
[23] MARC V, JOZEF B, MARC G. Brain and other natriuretic peptides: molecular aspects [J]. Eur J Heart Failure, 2004, 6: 261 - 268
[24] Keating GM,Goa KL. Nesiritide: a review of its uses in acute decompensated heart failure.Drugs.2003; 63:47-70
[25] Feil R, Lohmann SM, de Jonge H, et al. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice.Circ Res. 2003 Nov 14;93(10):907-16.
[26] [26] Burger AJ.A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail. 2005 Jan-Feb; 11(1):30-8
[27] Marcus LS, Hart D, Packer M, Yushak M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure.A double-blind, placebo-controlled, randomized crossover trial.Circulation. 1996; 94(12):3184-9.
[28] Yoshimura M, Yasue H, Morita E,et.al.Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.Circulation. 1991 Oct, 84(4):1581-8.
[29] Abraham WT, Lowes BD, Ferguson DA,et.al. Systemic hemodynamic, neurohormonal,and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.J Card Fail. 1998 Mar; 4(1):37-44.
[30] Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure.Am J Cardiol. 2002 Aug 15; 90(4):435-8.
[31] Kapoun AM, Liang F, O'Young G, et.al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation..Circ Res. 2004 Mar 5; 94(4):453-61.
[32] Spinale FG. .Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases.Circ Res. 2002 Dec 13; 91(12):1082-4.
[33] Mccullough PA,Omland T,Maisel AS.B-type natriuretic peptides:a diagnostic breakthrough for clinicians. Rev Cardiovasc Med, 2003, 4(2):72-80.
[34] Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, nitroprusside sodium-controlled clinical trial[J]. J Am Coll Cardiol, 2007, 50(19): 1835-1840
[35] Sackner BJD,Skopicki HA, Aaronson KD.Risk of worsening renal functions with nesiritide in patients with acutely decompensated heart failure [J]. Circulation, 2005,111(12):1487-1491
[36] Arora S, Clarke K, Srinivasan V, et al. Effect of nesiritide on renal function in patients admitted for decompensated heart failure [J].QJM. 2007, 100(11):699-706.
[37] ColucciWS, Elkayam U, HortonDP, et al. Intravenous nesiritide, a natriuretic pep tide, in the treatment of decompensated congestive heart failure [J]. N Engl J Med, 2000, 343:246-253.
[38] ColucciWS, Elkayam U, HortonDP, et al. Intravenous nesiritide, a natriuretic pep tide, in the treatment of decompensated congestive heart failure [J]. N Engl J Med, 2000, 343:246-253
[39] Costanzo MR, Hey wood JT, Emerman CL, et al. Evalution of in hospital mortality in patients treated for acute heart failure within the first 24 hours with nesiritide vs. other Vasoactive or introp ic agents [J]. Circulation, 2003, 108 (17 Supp 1 IV): 695
[40] Burger A J, Horton D P, Leje T, et al.The effect of nesiritide versus dobutamine on short2term outcomes in the treatment of patientswith acute decompensated heart failure [J]. J Am Coll Cardiol, 2002, 39 (5): 798 - 803.
[41] Colucci WS , Elkayam U , Horton DP, et all Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure-Nesiritide Study Group[J]1 N Engl J Med ,2000 ,343 :246-253.
[42] Aronson D,Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure[J]. Am J Cardiol, 2002, 90:435-438.
[43] Lainchbury JG, Richards AM, Nicholls MG,et al.The effect s of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction [J]. Hypertension, 1997,30 (3) :398-404.
[44] Sackner-Bernstein JD, Skopicki HA, Aa Sackner-Bernstein JD, et all Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized cont rolled trials [J]. JAMA, 2005, 293:1900-1905.
[45] Sackner-Bernstein JD, Skop icki HA, Aaronson KD.Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure [J]. Circulation, 2005, 111 (8):1487-1491.
[1]Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial[J].JAMA,2002,287(13):1531-1540
[2]Sudoh T,Kangawa K,Minamino N,et al.A new natriuretic pep tide in porcine brain[J].Nature,1988,332(10):78-86
[3] KUHN M. Molecular physiology of natriuretic pep tide signaling[J]. Basic Res Cardiol, 2004, 99 (2): 76 - 82.
[4] MARC V, JOZEF B,MARC G. Brain and other natriuretic peptides: molecular aspects[J]. Eur J Heart Failure, 2004,6: 261 - 268
[5] Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992 Jan; 130(1):229-39.
[6] McCullough PA, Omland T, Maisel AS.B-type natriuretic peptides: a diagnostic breakthrough for clinicians.Rev Cardiovasc Med. 2003;4(2):72-80.
[7] Ala-Kopsala M, Magga J, Peuhkurinen K,et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem.2004; 50(9): 1576-88.
[8] Qi W, Mathisen P, Kjekshus J,et al. Natriuretic peptides in patients with aortic stenosis.Am Heart J. 2001 Oct;142(4):725-32.
[9] Mccullough PA,Omland T,Maisel AS.B-type natriuretic peptides:a diagnostic breakthrough for clinicians. Rev Cardiovasc Med, 2003, 4(2):72-80.
[10]Feil R, Lohmann SM, de Jonge H, et al. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice.Circ Res. 2003 Nov 14;93(10):907-16.
[11] Burger AJ.A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail. 2005;11(1):30-8
[12]Marcus LS, Hart D, Packer M, Yushak M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996,15;94(12):3184-9.
[13]Yoshimura M, Yasue H, Morita E, et.al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.Circulation. 1991 Oct, 84(4):1581-8.
[14]Abraham WT, Lowes BD, Ferguson DA,et.al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998 Mar; 4(1):37-44.
[15]Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol. 2002 Aug 15; 90(4):435-8.
[16]Kapoun AM, Liang F, O'Young G, et.al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.Circ Res. 2004 Mar 5; 94(4):453-61.
[17]Spinale FG. Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases.Circ Res. 2002 Dec 13; 91(12):1082-4.
[18]Alan S M. B-type natriuretic pep tide (BNP) levels: diagnostic and therapeutic potential [J]. Rev Cardiovasc Med, 2001, 2 (Supp 12): 13 -18.
[19]Wieczorek SJ, Wu AH, Christenson R,et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J , 2002 ,144 :834 —839.
[20]McCullough PA , Nowak RM , McCord J , et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure :analysis from Breathing Not Properly (BNP) Multinational Study. Circulation, 2002, 106:416 -432.
[21]Maisel AS , McCord J , Nowak RM , et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction.Results from the Breathing Not Properly Multinational Study.J Am Coll Cardiol,2003,41:2010-2017.
[22]Ish Ⅱ A,Nomura M,Nakamura Y,et al.Risk stratification using a combination of cardiactroponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure[J].Am J Cardiol,2002,89:691-695.
[23]Berger R,Huelsman M,Stecker K,et al.B-type natriuretic peptide predicts sudden death in patients with chronic heart failure[J].Circulation,2002,105:2391-2396.
[24]毛拥军,张春华,刘松,等.脑钠肽与充血性心力衰竭的治疗[J].中华心血管病杂志,2004,32(9):855-857
[25]Krum H,Liew D.New and emerging drug therapies for the management of acute heart failure J[J].Intern Med,2003,33(11):515-520
[26]Witteles RM,Kao D,Christopherson D,et al.Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized,double-blind,placebo-controlled clinical trial.J Am Coll Cardiol.2007;50(19):1835-40
[27]ADHERE:the third quarter 2003 national benchmark report.
[28]Nieminen MS,Bohm M,Cowie MR,et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure:the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J.2005 Feb;26(4):384-416
[29]Colucci WS,Elkayam U,HortonDP,et al.Intravenous nesiritide,a natriuretic peptide,in the treatment of decompensated congestive heart failure[J].N Engl J Med,2000,343:246-253
[30]Costanzo MR,Heywood JT,Emerman CL,et al.Evalution of in hospital mortality in patients treated for acute heart failure within the first 24 hours with nesiritide vs.other vasoactive or intropic agents[J].Circulation,2003,108(17Supp 1 Ⅳ):695
[31]Burger A J,Horton D P,Leje T,et al.The effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acute decompensated heart failure[J].J Am Coll Cardiol,2002,39(5):798-803.
[32]Colucci WS,Elkayam U,Horton DP,et all Intravenous nesiritide,a natriuretic peptide,in the treatment of decompensated congestive heart failure-Nesiritide Study Group[J].N Engl J Med,2000,343:246-253.
[33]Aronson D,Burger AJ1 Intravenous nesiritide(human B-type natriuretic peptide)reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure[J].Am J Cardiol,2002,90:435-438.
[34]Lainchbury JG,Richards AM,Nicholls MG,et all The effect s of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction[J].Hypertension,1997,30(3):398-404.
[35]谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J].中华心血管病杂志,2006,34(3):222-225
[36]付尧,杨光,白小涓,等.重组人脑利钠肽治疗充血性心力衰竭的疗效评价[J].中国医科大学学报,2006,35(2):191-192
[37]李世强,傅向华,刘君,等.静脉注射重组人脑利钠肽对急性心肌梗死伴心力衰竭患者的急性血流动力学效应的研究[J].中华心血管病杂志,2006,34(1):29-33
[38]Sackner-Bemstein JD,Skopicki HA,Aa Sackner-Bemstein JD,et al.Short-term risk of death after treatment with nesiritide for decompensated heart failure:a pooled analysis of randomized cont rolled trials[J].JAMA,2005,293:1900-1905.
[39]Sackner-Bernstein JD,Skop icki HA,Aaronson KD.Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure [J]. Circulation, 2005, 111 (8) :1487-1491.
[40]Jonathan SB,Marcin K,Marshal F, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials [J]. JAMA, 2005,293 ( 15 ): 1900-1905.
[2]Massie BM,Shah NB.Evolving trends in the epidemiologic factors of heart failure:rational for preventive strategies and comprehensive disease management.Am Heart J,1997,133:703-712.
[3]2002 Heart and stroke statistica update.Dallas:American Heart Association,2001
[4]John R.Kapoor,Mar A.Perazella.Diagnostic and Therapeutic Approach to Acute Decompensated Heart Failure.The American Journal of Medicine.(2007) 120,121-127.
[5]HoKKL,Pinsky JL,Kannel WB,et al.The epidemiology of heart failure:the Framingham study.J Am Coll Cardiol,1993,22(SupplA):6A-13A
[6]Guidelines for the diagnosis and treatment of chronic heart failure:task force for the diagnosis and treatment of chronic heart failure.Eur Heart J,2001,22:1527-1560.
[7]顾东风,黄广勇,吴锡桂等.中国心力衰竭流行病学调查及其患病率.中华心血管病杂志,2003,(1).
[8]Lan'y A.Allen,Christopher M.O'Connor.Management of acute decompensated heart failure.CMAJ,2007;176(6),797-805
[9]Brunner-La,Rocca,H.P.,D.M.Kaye,et al.Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects.J Am Coll Cardiol 2001,37(5):1221-7.
[10]MaiselA.B --type natriuretic peptid elevels:A potential novel white count,for congestive heart failure. J Card Fail 2001; 7:183 — 193
[11]De Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile eurohormone. Chest; 2004; 125(2): 652-68
[12] Chen HH,Burnett JC.Natriuretic peptides in the pathophysiology of congestive heart failure.Curr Cardiol Rep,2000;2; 198-205
[13] Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007; 50(19):1835-40
[14] ADHERE:the third quarter 2003 national benchmark report.
[15] Nieminen MS, Bohm M, Cowie MR, et al .Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J.2005; 26(4):384-416
[16] Publication Committee for the VMAC Investigators.Intravenous nesiritide and nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial [J]. JAMA, 87(12):1531-1540.
[17] Sacchetti A, Ramoska E, Moakes ME, et al. Effect of ED management on ICU use in acute pulmonary edema. Am J Emerg Med. 1999; 17:571-574.
[18] Edoute Y, Roguin A, Behar D, et al. Prospective evaluation of pulmonary edema. Crit Care Med.2000; 28:330-335.
[19] Peacock F, Emerman C, Costanzo M, et al. Early initiation of intravenous Vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE registry database. Ann Emerg Med. 2003; 42:s29.
[20] John R. Kapoor, Mark A. Perazella, et al.Diagnostic and Therapeutic Approach to Acute Decompensated Heart Failure. The American Journal of Medicine, 2007; 120:121-127
[21] Sudoh T, Kangawa K,Minamino N, et al.A new natriuretic pep tide in porcine brain [J]. Nature, 1988, 332 (10): 78-86
[22] KUHN M.Molecular physiology of natriuretic peptide signaling[J]. Basic Res Cardiol, 2004, 99 (2): 76 - 82.
[23] MARC V, JOZEF B, MARC G. Brain and other natriuretic peptides: molecular aspects [J]. Eur J Heart Failure, 2004, 6: 261 - 268
[24] Keating GM,Goa KL. Nesiritide: a review of its uses in acute decompensated heart failure.Drugs.2003; 63:47-70
[25] Feil R, Lohmann SM, de Jonge H, et al. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice.Circ Res. 2003 Nov 14;93(10):907-16.
[26] [26] Burger AJ.A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail. 2005 Jan-Feb; 11(1):30-8
[27] Marcus LS, Hart D, Packer M, Yushak M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure.A double-blind, placebo-controlled, randomized crossover trial.Circulation. 1996; 94(12):3184-9.
[28] Yoshimura M, Yasue H, Morita E,et.al.Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.Circulation. 1991 Oct, 84(4):1581-8.
[29] Abraham WT, Lowes BD, Ferguson DA,et.al. Systemic hemodynamic, neurohormonal,and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.J Card Fail. 1998 Mar; 4(1):37-44.
[30] Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure.Am J Cardiol. 2002 Aug 15; 90(4):435-8.
[31] Kapoun AM, Liang F, O'Young G, et.al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation..Circ Res. 2004 Mar 5; 94(4):453-61.
[32] Spinale FG. .Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases.Circ Res. 2002 Dec 13; 91(12):1082-4.
[33] Mccullough PA,Omland T,Maisel AS.B-type natriuretic peptides:a diagnostic breakthrough for clinicians. Rev Cardiovasc Med, 2003, 4(2):72-80.
[34] Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, nitroprusside sodium-controlled clinical trial[J]. J Am Coll Cardiol, 2007, 50(19): 1835-1840
[35] Sackner BJD,Skopicki HA, Aaronson KD.Risk of worsening renal functions with nesiritide in patients with acutely decompensated heart failure [J]. Circulation, 2005,111(12):1487-1491
[36] Arora S, Clarke K, Srinivasan V, et al. Effect of nesiritide on renal function in patients admitted for decompensated heart failure [J].QJM. 2007, 100(11):699-706.
[37] ColucciWS, Elkayam U, HortonDP, et al. Intravenous nesiritide, a natriuretic pep tide, in the treatment of decompensated congestive heart failure [J]. N Engl J Med, 2000, 343:246-253.
[38] ColucciWS, Elkayam U, HortonDP, et al. Intravenous nesiritide, a natriuretic pep tide, in the treatment of decompensated congestive heart failure [J]. N Engl J Med, 2000, 343:246-253
[39] Costanzo MR, Hey wood JT, Emerman CL, et al. Evalution of in hospital mortality in patients treated for acute heart failure within the first 24 hours with nesiritide vs. other Vasoactive or introp ic agents [J]. Circulation, 2003, 108 (17 Supp 1 IV): 695
[40] Burger A J, Horton D P, Leje T, et al.The effect of nesiritide versus dobutamine on short2term outcomes in the treatment of patientswith acute decompensated heart failure [J]. J Am Coll Cardiol, 2002, 39 (5): 798 - 803.
[41] Colucci WS , Elkayam U , Horton DP, et all Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure-Nesiritide Study Group[J]1 N Engl J Med ,2000 ,343 :246-253.
[42] Aronson D,Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure[J]. Am J Cardiol, 2002, 90:435-438.
[43] Lainchbury JG, Richards AM, Nicholls MG,et al.The effect s of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction [J]. Hypertension, 1997,30 (3) :398-404.
[44] Sackner-Bernstein JD, Skopicki HA, Aa Sackner-Bernstein JD, et all Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized cont rolled trials [J]. JAMA, 2005, 293:1900-1905.
[45] Sackner-Bernstein JD, Skop icki HA, Aaronson KD.Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure [J]. Circulation, 2005, 111 (8):1487-1491.
[1]Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial[J].JAMA,2002,287(13):1531-1540
[2]Sudoh T,Kangawa K,Minamino N,et al.A new natriuretic pep tide in porcine brain[J].Nature,1988,332(10):78-86
[3] KUHN M. Molecular physiology of natriuretic pep tide signaling[J]. Basic Res Cardiol, 2004, 99 (2): 76 - 82.
[4] MARC V, JOZEF B,MARC G. Brain and other natriuretic peptides: molecular aspects[J]. Eur J Heart Failure, 2004,6: 261 - 268
[5] Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992 Jan; 130(1):229-39.
[6] McCullough PA, Omland T, Maisel AS.B-type natriuretic peptides: a diagnostic breakthrough for clinicians.Rev Cardiovasc Med. 2003;4(2):72-80.
[7] Ala-Kopsala M, Magga J, Peuhkurinen K,et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem.2004; 50(9): 1576-88.
[8] Qi W, Mathisen P, Kjekshus J,et al. Natriuretic peptides in patients with aortic stenosis.Am Heart J. 2001 Oct;142(4):725-32.
[9] Mccullough PA,Omland T,Maisel AS.B-type natriuretic peptides:a diagnostic breakthrough for clinicians. Rev Cardiovasc Med, 2003, 4(2):72-80.
[10]Feil R, Lohmann SM, de Jonge H, et al. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice.Circ Res. 2003 Nov 14;93(10):907-16.
[11] Burger AJ.A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail. 2005;11(1):30-8
[12]Marcus LS, Hart D, Packer M, Yushak M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996,15;94(12):3184-9.
[13]Yoshimura M, Yasue H, Morita E, et.al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.Circulation. 1991 Oct, 84(4):1581-8.
[14]Abraham WT, Lowes BD, Ferguson DA,et.al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998 Mar; 4(1):37-44.
[15]Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol. 2002 Aug 15; 90(4):435-8.
[16]Kapoun AM, Liang F, O'Young G, et.al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.Circ Res. 2004 Mar 5; 94(4):453-61.
[17]Spinale FG. Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases.Circ Res. 2002 Dec 13; 91(12):1082-4.
[18]Alan S M. B-type natriuretic pep tide (BNP) levels: diagnostic and therapeutic potential [J]. Rev Cardiovasc Med, 2001, 2 (Supp 12): 13 -18.
[19]Wieczorek SJ, Wu AH, Christenson R,et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J , 2002 ,144 :834 —839.
[20]McCullough PA , Nowak RM , McCord J , et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure :analysis from Breathing Not Properly (BNP) Multinational Study. Circulation, 2002, 106:416 -432.
[21]Maisel AS , McCord J , Nowak RM , et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction.Results from the Breathing Not Properly Multinational Study.J Am Coll Cardiol,2003,41:2010-2017.
[22]Ish Ⅱ A,Nomura M,Nakamura Y,et al.Risk stratification using a combination of cardiactroponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure[J].Am J Cardiol,2002,89:691-695.
[23]Berger R,Huelsman M,Stecker K,et al.B-type natriuretic peptide predicts sudden death in patients with chronic heart failure[J].Circulation,2002,105:2391-2396.
[24]毛拥军,张春华,刘松,等.脑钠肽与充血性心力衰竭的治疗[J].中华心血管病杂志,2004,32(9):855-857
[25]Krum H,Liew D.New and emerging drug therapies for the management of acute heart failure J[J].Intern Med,2003,33(11):515-520
[26]Witteles RM,Kao D,Christopherson D,et al.Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized,double-blind,placebo-controlled clinical trial.J Am Coll Cardiol.2007;50(19):1835-40
[27]ADHERE:the third quarter 2003 national benchmark report.
[28]Nieminen MS,Bohm M,Cowie MR,et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure:the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J.2005 Feb;26(4):384-416
[29]Colucci WS,Elkayam U,HortonDP,et al.Intravenous nesiritide,a natriuretic peptide,in the treatment of decompensated congestive heart failure[J].N Engl J Med,2000,343:246-253
[30]Costanzo MR,Heywood JT,Emerman CL,et al.Evalution of in hospital mortality in patients treated for acute heart failure within the first 24 hours with nesiritide vs.other vasoactive or intropic agents[J].Circulation,2003,108(17Supp 1 Ⅳ):695
[31]Burger A J,Horton D P,Leje T,et al.The effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acute decompensated heart failure[J].J Am Coll Cardiol,2002,39(5):798-803.
[32]Colucci WS,Elkayam U,Horton DP,et all Intravenous nesiritide,a natriuretic peptide,in the treatment of decompensated congestive heart failure-Nesiritide Study Group[J].N Engl J Med,2000,343:246-253.
[33]Aronson D,Burger AJ1 Intravenous nesiritide(human B-type natriuretic peptide)reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure[J].Am J Cardiol,2002,90:435-438.
[34]Lainchbury JG,Richards AM,Nicholls MG,et all The effect s of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction[J].Hypertension,1997,30(3):398-404.
[35]谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J].中华心血管病杂志,2006,34(3):222-225
[36]付尧,杨光,白小涓,等.重组人脑利钠肽治疗充血性心力衰竭的疗效评价[J].中国医科大学学报,2006,35(2):191-192
[37]李世强,傅向华,刘君,等.静脉注射重组人脑利钠肽对急性心肌梗死伴心力衰竭患者的急性血流动力学效应的研究[J].中华心血管病杂志,2006,34(1):29-33
[38]Sackner-Bemstein JD,Skopicki HA,Aa Sackner-Bemstein JD,et al.Short-term risk of death after treatment with nesiritide for decompensated heart failure:a pooled analysis of randomized cont rolled trials[J].JAMA,2005,293:1900-1905.
[39]Sackner-Bernstein JD,Skop icki HA,Aaronson KD.Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure [J]. Circulation, 2005, 111 (8) :1487-1491.
[40]Jonathan SB,Marcin K,Marshal F, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials [J]. JAMA, 2005,293 ( 15 ): 1900-1905.